À titre de membre permanent, vous pourrez accéder au contenu éditorial et de formation continue, utiliser le moteur de recherche, recevoir nos newsletters, participer aux discussions, télécharger des diapositives et plus encore.
The absolute reduction in VTE risk was 0.76%, meaning that for every 125 patients treated with apixaban instead of enoxaparin, clinicians would prevent one episode of major VTE, report investigators.
Discussion as to what role the new oral anticoagulant rivaroxaban might play in the treatment of venous thromboembolism was the subject of a press conference at the American Society of Hematology meeting today. Hematologists gave heartwire their view on the issue.
